Highly potent growth hormone secretagogues: hybrids of NN703 and ipamorelin
- PMID: 11459660
- DOI: 10.1016/s0960-894x(01)00345-6
Highly potent growth hormone secretagogues: hybrids of NN703 and ipamorelin
Abstract
A series of NN703 analogues with lysine mimetics combined with naphthyl- or biphenylalanine in the core has been prepared and tested in vitro in a rat pituitary cell based assay and subsequently in vivo in pigs in a single dose at 50 nmol/kg. Re-introduction of certain pharmacophores in the C-terminal of NN703, which were originally removed during optimisation for oral bioavailability, led to unexpectedly potent compounds in vitro as well as in vivo.
Similar articles
-
Growth hormone secretagogues derived from NN703 with hydrazidesas c-terminal.Eur J Med Chem. 2000 May;35(5):487-97. doi: 10.1016/s0223-5234(00)00146-x. Eur J Med Chem. 2000. PMID: 10889328
-
Pharmacological characterisation of a new oral GH secretagogue, NN703.Eur J Endocrinol. 1999 Aug;141(2):180-9. doi: 10.1530/eje.0.1410180. Eur J Endocrinol. 1999. PMID: 10427162
-
Novel orally active growth hormone secretagogues.J Med Chem. 1998 Sep 10;41(19):3705-14. doi: 10.1021/jm980197u. J Med Chem. 1998. PMID: 9733496
-
A new receptor for growth hormone-release peptide.Science. 1996 Aug 16;273(5277):923. doi: 10.1126/science.273.5277.923. Science. 1996. PMID: 8711477 Review. No abstract available.
-
Orally active growth hormone secretagogues.Pharm Biotechnol. 1998;11:525-54. doi: 10.1007/0-306-47384-4_23. Pharm Biotechnol. 1998. PMID: 9760695 Review. No abstract available.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical